TABLE 5.

Heterogeneity of SGLT2i on Primary Outcome 3-Point MACE^*

	Established CVD	CVD Risk Factors	p Value for Interaction
	HR (95% CI)	HR (95% CI)
EMPA-REG (82)	0.66 (0.55–0.79)	NA
CANVAS (83)	0.82 (0.72–0.95)	0.98 (0.77–1.03)	0.18
CREDENCE (84)	0.70 (0.56–0.88)	0.69 (0.54–0.88)	0.91
DECLARE-TIMI 58 (85)	0.90 (0.79–1.02)	1.01 (0.86–1.02)	0.25

^*There is a class effect of SGLT2i for secondary prevention of 3-point MACE.

CI = confidence interval; CVD = cardiovascular disease; HR = hazard ratio; MACE = major adverse cardiovascular events; SGLT2i = sodium-glucose cotransporter-2 inhibitor; other abbreviations as in Tables 3 and 4.